Countries in North America and Europe have the highest incidence of inflammatory disorders of the gastrointestinal tract. The prevalence of inflammatory bowel diseases (IBD), which comprise Crohn's disease (CD) and ulcerative colitis (UC), now ranges from 10-200 cases per 100 000 individuals [1] . Although new therapeutic approaches have been developed to improve current treatments, the etiology of this disorder remains elusive. Crohn's disease and ulcerative colitis are known to show similar clinical and pathological characteristics; however it is now believed that these two forms of IBD are entirely different. Epidemiological studies have revealed that these differences might be explained by the fact that environmental and genetic factors play important roles in the pathogenesis and susceptibility to IBD [1] . Over the years, significant advances in the study of IBD had been made through the analysis of patient-based studies and murine models of intestinal inflammation [1] . One important feature characterizing IBD is the alteration of mucosal immunity, caused by effector T cell dysfunction and aberrant pro-inflammatory cytokine production. Indeed, mice with mutations in genes regulating T-cell immune responses or expressing specific transgenes were shown to develop spontaneous colitis. These murine models have greatly contributed to our understanding of human IBD [1] .
Interestingly, genetic linkage studies have demonstrated that the gene coding for G protein subunit Gi2 alpha (Gai2) is located within an IBD susceptible locus on chromosome 3p21 [2] and therefore is a potential candidate for IBD development in humans. In 1995, Rudolph et al. observed that Gai2-deficient mice developed spontaneous inflammatory bowel disease closely resembling ulcerative colitis in humans [3] . The authors also demonstrated that an increase in the production of pro-inflammatory T H 1 cytokines such as IL-12, TNF-a and IFN-g in the intestinal mucosa of these Gai2-deficient mice led to a dysregulation in T cell activation. In fact, overproduction of these cytokines resulted in an upregulation of effector T cells and downregulation of naїve T cells, suggesting an important role for Gai2 in the negative regulation of T cell response [4] . Further phenotypic analysis revealed that the number of Peyer's patches, which are the primary site for antigen encounter in the gut and specialised sites for initiation of mucosal immune responses [5] , was also decreased in Gai2-deficient mice.
In a recent issue of Cell Research, Wang Yi et al. [6] report that disruption of the retinoid acid-inducible gene-I (RIG-I) in mice leads to a colitis-like phenotype that is associated with the downregulation of Gai2 expression. RIG-I is an intracellular pathogen-recognition receptor (PRR) that recognizes a variety of RNA viruses and triggers the innate antiviral response independent of the Tolllike receptor (TLR)-dependent pathways. RIG-I contains a DExD/H box RNA helicase domain and two caspase activation and recruitment domains (CARD). Binding of dsRNA and specifically 5′-triphosphate containing RNA to its DExD/H box leads to IFN production in response to viral infection via its interaction with downstream signalling protein MAVS and activation of IRF-3 and NF-kB (reviewed in [7] ).
Wang Yi et al. successfully generated RIG-I-deficient mice through the deletion of exons 4 to 8 of the RIG-I gene. Interestingly, mice generated using this strategy were viable and fertile, in contrast to a previously reported study by Kato et al. [8] , where RIG -/-mice were severely affected by RIG-I gene ablation and died during embryogenesis. These striking phenotypic differences between the two studies likely reflected the disruption of different regions of the RIG-I gene. Nevertheless, the generation of these knockout mice provides a valuable alternate mouse model npg for the study of the mechanisms underlying IBD.
Wang Yi et al. demonstrate that RIG -/-mice experience a decrease in body weight and histological analysis of the colons of these mice reveals a colitis-like phenotype that correlates with severe damage and inflammatory infiltration in the colon mucosa. Consistent with previous observations that a decreased number of Peyer's patches was associated with the development of colitis [9] , this study also demonstrated that the number and size of Peyer's patches were significantly reduced in RIG -/-mice. The authors then asked if RIG -/-mice display an altered regulation in T cell activation, as observed in other murine models of IBD such as Gai2 -/-mice. Similar to Gai2 -/-mice, RIG-I deficiency leads to an increase in splenic CD4
+ and CD8 + effector T cells and a decrease in naїve T cells, suggesting that RIG-I plays an essential role in the regulation of T cell activation. As Gai2-or RIG-I-deficient mice display similar phenotypes, the possible link between Gai2 function and RIG-I was further evaluated. The authors demonstrated that Gai2 expression is decreased in various tissues, as well as in T and B cells isolated from spleens of RIG -/-mice. Moreover, reporter assays demonstrated that RIG-I overexpression induced Gai2 promoter activity, thus indicating that RIG-I regulates the transcriptional activity of Gai2. Regulation of the Gai2 promoter by RIG-I may be mediated by the activation of the NF-kB pathway [10] .
In summary, the report by Wang Yi et al. underlines the importance of Gai2-deficiency in the development of colitis. RIG-I may be a key player in the regulation of Gai2 expression and thus RIG-I deficiency may contribute to the pathogenesis of IBD. Future work investigating RIG-I expression levels in individuals suffering from ulcerative colitis would further test this idea. Strikingly, another intracellular pathogen sensor − NOD2 − has also been associated with the development of Crohn's disease. Indeed, mutations of the NOD2 gene − also known as caspase-recruitment domain protein 15 (CARD15) − have been shown to occur exclusively in patients with Crohn's disease and not in patients with ulcerative colitis (reviewed in [1] ). Altogether, these studies highlight the involvement of pattern recognition receptors in the pathogenesis of inflammatory bowel disease. Although further research is required to enhance our knowledge of the exact causes of IBD pathogenesis, these findings will ultimately contribute to the development of new therapies.
